Figure 6.
Associations between survival probability and mutations in pretreatment tumor samples. Hazards ratios (HRs) are shown separately for pretreatment samples of rrDLBCL and all DLBCL including cured disease. HR and P values were corrected by the COO and IPI score. (A, B) Genes with P values < 0.05 in the univariate analysis for rrDLCL are included. (C, D) Pathways with > 9 mutated rrDLBCL samples are included.